Celldex Therapeutics Initiates Accelerated Approval Study of Glembatumumab Vedotin in Patients with Triple Negative Breast Cancer

Celldex Therapeutics (Nasdaq: CLDX ) today announced that it has launched a randomized study (METRIC) of Glembatumumab vedotin (CDX-011) in patients with metastatic triple negative breast cancers that over-express glycoprotein NMB (gpNMB). Glembatumumab vedotin is an antibody-drug conjugate that targets and binds to gpNMB, a specific protein that is